Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | NOS3 | P29474 | 1/20 | 0.54 |
| ▸ | NOS1 | P29475 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL15366234 | 0.98 | MAPT (0.59) | MAPTGAAHTTCYP19A1HDAC1 | |
| SCHEMBL27680592 | 0.92 | MAPT (0.54) | MAPTGAAHTTCYP19A1HDAC1 | |
| Selenium SCHEMBL10541726 | 0.92 | MAPT (0.54) | MAPTGAAHTTCYP19A1HDAC1 | |
| SCHEMBL28064719 | 0.91 | CA12 (0.59) | MAPTGAAHTTCYP19A1HDAC1 | |
| SCHEMBL3433732 | 0.85 | GAA (0.59) | MAPTGAAHTTCYP19A1HDAC1 | |
| SCHEMBL22181781 | 0.85 | CA12 (0.71) | MAPTGAAHTTCYP19A1HDAC1 | |
| SCHEMBL14256403 | 0.85 | HTT (0.68) | MAPTGAAHTTCYP19A1HDAC1 | |
| SCHEMBL15081591 | 0.84 | HTT (0.61) | MAPTGAAHTTCYP19A1HDAC1 | |
| SCHEMBL3519967 | 0.83 | MAPT (0.54) | MAPTGAAHTTCYP19A1HDAC6 | |
| SCHEMBL28120381 | 0.83 | HTT (0.57) | MAPTGAAHTTCYP19A1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 619 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026047173-A1 | PROCESS FOR PREPARING SUSTAINABLE JET FUELS OR DIESEL FUELS; AND PRECURSORS THEREOF | Terra Mater BV (BE) | 2026-03-05 | — | — | WO | claimed |
| EP-4622945-A1 | OLIGOMERISATION OF ALCOHOLS | Terra Mater BV (BE) | 2025-10-01 | — | — | EP | claimed |
| WO-2024110575-A1 | OLIGOMERISATION OF ALCOHOLS | Terra Mater BV (BE) | 2024-05-30 | — | — | WO | claimed |
| US-20240043809-A1 | Intestinal organoid co-culture systems and methods for treating or preventing a disease or disorder associated with immune response-mediated tissue injury | NEW YORK UNIVERSITY | 2024-02-08 | — | — | US | claimed |
| CN-115894373-A | N-substituted benzylpyrazole derivatives as beta 2 Use of allosteric modulators, antagonists and agonists of the adrenergic receptor | 常州大学 | 2023-04-04 | — | — | CN | claimed |
| CN-112778202-B | Benzyl pyrazole ionic liquid compound and preparation method and application thereof | 河南大学 | 2022-07-05 | — | — | CN | claimed |
| EP-3288942-B1 | RSV ANTIVIRAL PYRAZOLO- AND TRIAZOLO-PYRIMIDINE COMPOUNDS | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2021-10-27 | — | — | EP | claimed |
| US-11084826-B2 | RSV antiviral pyrazolo- and triazolo-pyrimidine compounds | Janssen Sciences Ireland Unlimited Company (IE) | 2021-08-10 | — | — | US | claimed |
| US-20210139857-A1 | Intestinal organoid co-culture systems and methods for treating or preventing a disease or disorder associated with immune response-mediated tissue injury | NEW YORK UNIVERSITY | 2021-05-13 | — | — | US | claimed |
| CN-112778202-A | Benzyl pyrazole ionic liquid compound and preparation method and application thereof | 河南大学 | 2021-05-11 | — | — | CN | claimed |
| US-20050261206-A1 | Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof | KISSEI PHARMACEUTICAL CO., LTD. | 2005-11-24 | — | — | US | claimed |
| WO-2005020897-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | DENDREON CORPORATION (US) | 2005-03-10 | — | — | WO | claimed |
| US-20040147729-A1 | Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof | KISSEI PHARMACEUTICAL CO., LTD. | 2004-07-29 | — | — | US | claimed |
| EP-1213296-B1 | GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THE SAME AND INTERMEDIATES IN THE PRODUCTION THEREOF | KISSEI PHARMACEUTICAL (JP) | 2004-04-14 | — | — | EP | claimed |
| EP-1213296-A1 | GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THE SAME AND INTERMEDIATES IN THE PRODUCTION THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2002-06-12 | — | — | EP | claimed |
| EP-0751944-B1 | THIAZOLIDINES AND OXAZOLIDINES SUBSTITUTED BY A PYRIDINE RING AND THEIR USE AS HYPOGLYCEMIC AGENTS | NISSAN CHEMICAL IND LTD (JP) | 2000-12-20 | — | — | EP | claimed |
| US-5955481-A | Pyridine type thiazolidines | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1999-09-21 | — | — | US | claimed |
| EP-0751944-A1 | THIAZOLIDINES AND OXAZOLIDINES SUBSTITUTED BY A PYRIDINE RING AND THEIR USE AS HYPOGLYCEMIC AGENTS | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1997-01-08 | — | — | EP | claimed |
| WO-1995026347-A1 | THIAZOLIDINES AND OXAZOLIDINES SUBSTITUTED BY A PYRIDINE RING AND THEIR USE AS HYPOGLYCEMIC AGENTS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1995-10-05 | — | — | WO | claimed |
| US-5409893-A | Administering with platinum complexes | BOEHRINGER MANNHEIM ITALIA, S.P.A. (IT) | 1995-04-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11084826-B2 | RSV antiviral pyrazolo- and triazolo-pyrimidine compounds | ZC3HAV1, MAVS, TYMP | MAPT 3325/4885GAA 2343/4885HTT 4378/4885 |
| US-20040147729-A1 | Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof | SLC5A1, SLC5A2, UGGT1 | MAPT 2024/4885GAA 300/4885HTT 1455/4885 |
| US-20050261206-A1 | Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof | SLC5A1, SLC5A2, UGGT1 | MAPT 1571/4885GAA 302/4885HTT 1321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.